⟵ Back to Search Results

BGB-3111-308

Recruiting

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Ask to Join

Beigene Study ID info

BGB-3111-308

ClinicalTrials.gov ID info

NCT05100862

EudraCT Number info

2022-502548-12-00

China Drug Trials ID info

CTR20232545

Study Overview

Sex: All

Age: 18 Years / N/A

Accepts Healthy Volunteers? yes

No Study Documents

Locations

Study Overview

Sex: All

Age: 18 Years / N/A

Accepts Healthy Volunteers? yes

No Study Documents